Dare Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DARE research report →
Range $1 – $2
Price Chart
About the company
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
- CEO
- Sabrina Martucci Johnson
- IPO
- 2014
- Employees
- 23
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on DARE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.01M
- P/E
- -0.59
- Fwd P/E
- 0.76
- PEG
- -0.00
- P/S
- 5.68
- P/B
- 3.03
- EV/EBITDA
- 0.30
- Div Yield
- 0.00%
- Gross Margin
- -12.88%
- Op Margin
- -746.14%
- Net Margin
- -749.82%
- ROE
- -789.97%
- ROIC
- -115.35%
Latest fiscal year · YoY change
- Revenue
- $1.03M+10429.4%
- Gross Profit
- $-1,416,987+90.1%
- Op Income
- $-13,552,334
- Net Income
- $-13,399,274-230.6%
- EPS
- $-1.20-150.0%
- OCF Growth
- -283.3%
- FCF Growth
- -313.0%
- 52W High
- $3.78
- 52W Low
- $0.41
- 50D MA
- $0.70
- 200D MA
- $1.48
- Beta
- 1.15
- RSI (14)
- 24
- Avg Volume
- 242.39K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Daré Bioscience highlighted early commercial traction for Flora Sync LF5 and imminent dispensing of DARE to PLAY Sildenafil Cream, while continuing to lean on nondilutive funding to advance its pipeline.· November 16, 2026
- Flora Sync LF5 is in market and has already reached 27 states, with the first provider office reorder and a 4.9-star rating after about 25 reviews.
- DARE to PLAY Sildenafil Cream prescriptions have been written by 182 office-based providers before dispensing begins, with written prescriptions across 48 states and the District of Columbia including telehealth.
- Management said DARE to PLAY product is en route to Medvantx and expects prescription dispensing to begin in November, initially in the 28 states where the outsourcing facility is licensed.
- Two later-stage programs, Ovaprene and DARE-HPV, are moving toward data readouts in 2027, while grant funding continues to support DARE-LARC1 and DARE-PTB2.
- Cash was approximately $11.5 million at quarter-end, and the company reiterated a capital-light strategy that uses external funding and collaborations where possible.
For the third quarter of 2026, Daré reported revenue of approximately $48,000 versus approximately $2,000 in the third quarter of 2025. Revenue primarily reflected research and development services, and also included initial sales of Flora Sync LF5, which began in July. SG&A was approximately $2.6 million versus approximately $2.5 million a year ago, while R&D expense was approximately $0.3 million versus approximately $1.2 million in the prior-year period; the company said lower R&D spending reflected reduced activity across several programs, partially offset by higher DARE-HPV costs. Net loss was approximately $3.2 million versus approximately $3.6 million in the third quarter of 2025. Cash and cash equivalents were approximately $11.5 million and working capital was approximately $3.2 million as of September 30, 2026. The company did not provide formal next-quarter or full-year financial guidance on the call; instead, it said the key near-term priorities are building repeat demand for Flora Sync LF5, beginning DARE to PLAY dispensing in November, and moving Ovaprene and DARE-HPV toward 2027 readouts.
Sabrina Johnson framed the quarter as evidence that Daré’s dual-path strategy is starting to take shape, with a marketed product, an imminent prescription launch, and a pipeline that can still grow through 2027. Her tone was confident and execution-focused: she repeatedly emphasized disciplined commercialization, trusted provider relationships, and keeping control of pricing and brand economics across multiple channels. She also pointed to national attention on women’s health and the company’s platform technologies as sources of future opportunity.
MarDee Haring-Layton focused on the quarter’s reported financials and balance sheet. She said cash and cash equivalents were approximately $11.5 million and working capital approximately $3.2 million at September 30, 2026. She also highlighted that R&D expense was only approximately $0.3 million because of nondilutive funding and cautioned investors not to view that low number as a proxy for the company’s actual development activity across the portfolio.
Analysts focused on where Flora Sync LF5 and DARE to PLAY will be sold, how broad the channel strategy could become, and what the company’s addressable market really looks like. Management said Flora Sync LF5 is currently sold through the DARE Health Hub and clinician offices, with Amazon planned for early 2027 and other online and brick-and-mortar channels possible later. On DARE to PLAY, Sabrina Johnson said it will be available through the DARE Health Hub, office-based prescribers, and select telehealth partnerships like MyMenopauseRx, while some clinicians may also stock and dispense it directly; she said dispensing starts in 28 states where the 503B outsourcing facility is licensed. When asked about inventory, she clarified that Flora Sync inventory sits on Daré’s books, but DARE to PLAY inventory belongs to the 503B outsourcing facility and Daré will book net proceeds rather than gross product inventory.
The call showed tangible early commercial signals: Flora Sync LF5 is already generating orders and repeat activity, and DARE to PLAY has prescriptions written before product availability. Management also described a broadening multi-channel strategy, including Amazon for Flora Sync and partnerships like MyMenopauseRx, which could support access and awareness without relying on one channel. External funding remains a meaningful support for the pipeline, helping the company pursue multiple programs without as much dilution.
The company is still very early in commercialization, and management explicitly said Flora Sync revenue in the first month is not material. DARE to PLAY is not yet broadly available, is limited at first to 28 states, and depends on a 503B outsourcing/fillment setup that could constrain scale. Financially, cash was only approximately $11.5 million at quarter-end, and the company did not provide formal revenue or earnings guidance, leaving investors reliant on execution rather than near-term financial visibility.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.3%
- Shares Outstanding
- 19.67M
- Float Shares
- 17.36M
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 632.87K | ▼ 8.01K |
| Vanguard Group Inc | 523.05K | ▲ 128.16K |
| Ubs Group AG | 239.60K | ▲ 232.79K |
| Us Bancorp \De\ | 220.92K | ▲ 100.00K |
| Geode Capital Management, LLC | 152.41K | ▲ 12.31K |
| Vanguard Fiduciary Trust Co | 91.27K | 0 |
| Blackrock, Inc. | 62.16K | ▼ 2.09K |
| State Street Corp | 47.41K | 0 |
| Citadel Advisors LLC | 45.14K | ▲ 45.14K |
| Xtx Topco Ltd | 37.38K | ▲ 37.38K |
| Hrt Financial LP | 37.34K | ▲ 14.91K |
| Northern Trust Corp | 34.21K | 0 |
Held by 21 ETFs
Biggest fund positions in DARE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | RASTETTER WILLIAM H | sell | 859 |
| Jun 30, 26 | Grossman Jessica D. | other | 26,066 |
| Jun 30, 26 | Kelley Susan L. | other | 23,696 |
| Jun 30, 26 | Matz Gregory W | other | 30,805 |
| Jun 30, 26 | RASTETTER WILLIAM H | other | 38,862 |
| Jun 30, 26 | Steele Robin Joan | other | 26,540 |
| Jun 11, 26 | RASTETTER WILLIAM H | other | 10,000 |
| Jun 11, 26 | Kelley Susan L. | other | 10,000 |
| Jun 11, 26 | Steele Robin Joan | other | 10,000 |
| Jun 11, 26 | Matz Gregory W | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DARE coverage
Recent articles, reports, and earnings notes.
No research on DARE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DARE report →Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 17
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 16
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
globenewswire.com · Nov 16
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding
globenewswire.com · Nov 16
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
globenewswire.com · Nov 10
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
globenewswire.com · Nov 9
Daré Bioscience to Present at Stifel's 2026 Healthcare Conference
globenewswire.com · Nov 4
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
globenewswire.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.